Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC

To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma

Inclusion Criteria: 1. Aged 18-70 years, male or female; 2. Have not received systemic or localized treatment in the past; 3. Histologically or cytologically confirmed esophageal squamous cell carcinoma (AJCC 8th edition clinical stage II-IVA). IVB stage thoracic esophageal cancer with supraclavicular lymph node metastasis only. No surgical resection or refusal of surgical resection; 4. ECOG score of 0-1; 5. Life expectancy ≥ 3 months; 6. Adequate organ function; 7. Fertile men and women must agree to use contraception during the study period and for six months after the last drug used in the study； 8. Subjects will voluntarily enroll in the study, sign an informed consent form, be compliant, and cooperate with follow-up visits. Exclusion Criteria: 1. Subjects with low body weight (BMI \